Podcasts about cytomegalovirus cmv

Did you know that congenital cytomegalovirus (cCMV) is the most common congenital viral infection in newborns and a leading cause of non-genetic hearing loss? Despite its prevalence, awareness and screening for cCMV remain inconsistent across healthcare systems. In this episode, we dive into the critical importance of cCMV screening, early diagnosis, and intervention. Join our expert guests Dr. Ingrid Camelo and Dr. John Noel as they discuss: The impact of cCMV on neonatal and long-term health outcomes Best practices for screening and diagnostic methods The role of early intervention, including antiviral therapy How advocacy efforts are shaping the future of universal screening policies Tune in to stay informed on how pediatricians and healthcare providers can play a vital role in improving outcomes for infants affected by cCMV. Special thanks to Dr. James Grubbs for peer reviewing this episode. CME Credit (requires free sign up): Link Coming Soon! References:  American Academy of Pediatrics. A targeted approach for congenital cytomegalovirus. Available at: https://publications.aap.org/pediatrics/article/139/2/e20162128/60211/A-Targeted-Approach-for-Congenital-Cytomegalovirus. Accessed August 13, 2024. Chiopris G, Veronese P, Cusenza F, Procaccianti M, Perrone S, Daccò V, Colombo C, Esposito S. Congenital cytomegalovirus infection: update on diagnosis and treatment. Microorganisms. 2020 Oct 1;8(10):1516. doi: 10.3390/microorganisms8101516. PMID: 33019752; PMCID: PMC7599523. Gantt S. Newborn cytomegalovirus screening: is this the new standard? Curr Opin Otolaryngol Head Neck Surg. 2023 Dec 1;31(6):382-387. doi: 10.1097/MOO.0000000000000925. Epub 2023 Oct 11. PMID: 37820202. Minnesota Department of Health. Minnesota implements universal newborn screening for cytomegalovirus. Available at: https://www.health.state.mn.us/news/pressrel/2023/ccmv020823.html. Accessed August 13, 2024. National CMV Foundation. Advocacy: universal newborn CMV screening. Available at: https://www.nationalcmv.org/about-us/advocacy#:~:text=Minnesota%20was%20the%20first%20state%20to%20enact%20universal%20newborn%20CMV%20screening. Accessed August 13, 2024. New York State Department of Health. Newborn screening for cytomegalovirus. Available at: https://www.health.ny.gov/press/releases/2023/2023-09-29_newborn_screening.htm#:~:text=ALBANY%2C%20N.Y.,all%20babies%20for%20the%20virus. Accessed August 13, 2024. UpToDate. Congenital cytomegalovirus (CMV) infection: clinical features and diagnosis. Available at: https://www.uptodate.com/contents/congenital-cytomegalovirus-ccmv-infection-clinical-features-and-diagnosis?search=cmv%20screening&source=search_result&selectedTitle=1%7E28&usage_type=default&display_rank=1#H92269684. Accessed August 13, 2024. UpToDate. Congenital cytomegalovirus (CMV) infection: management and outcome. Available at: https://www.uptodate.com/contents/congenital-cytomegalovirus-ccmv-infection-management-and-outcome?search=congenital%20cmv&source=search_result&selectedTitle=2%7E66&usage_type=default&display_rank=2. Accessed August 13, 2024. UpToDate. Ganciclovir and valganciclovir: an overview. Available at: https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview?search=ganciclovir&source=search_result&selectedTitle=2%7E80&usage_type=default&display_rank=1#H6. Accessed August 13, 2024. University of Texas Medical Branch. Neonatology manual: infectious diseases. Available at: https://www.utmb.edu/pedi_ed/NeonatologyManual/InfectiousDiseases/InfectiousDiseases3.html#:~:text=may%20be%20required.-,Cytomegalovirus,Clinical%20findings. Accessed August 13, 2024. National Center for Biotechnology Information. Cytomegalovirus (CMV) infection. Available at: https://www.ncbi.nlm.nih.gov/books/NBK541003/. Accessed August 13, 2024.                                                                                                             

Send us a Text Message.In this episode of "The Autoimmune RESET," VJ explores Stiff Person Syndrome (SPS), a rare and complex neurological disorder marked by severe muscle stiffness and spasms. With its autoimmune roots, SPS is often linked to other conditions like type 1 diabetes and vitiligo. VJ dives deep into the science behind SPS, focusing on its connection to pathogens such as Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV). Learn how these infections might trigger or worsen SPS through mechanisms like molecular mimicry and bystander activation.We'll also discuss how SPS affects daily life, from the challenges of managing overstimulation and muscle control to its impact on high-profile cases like Celine Dion's career. Understand how SPS influences her ability to perform and the adjustments needed for managing symptoms while maintaining a demanding schedule.You will gain practical advice on living with SPS, including nutritional strategies, natural therapies, and stress management techniques that can help mitigate symptoms. Whether you're living with SPS, know someone who is, or are simply curious about this condition, this episode provides a thorough and compassionate overview of SPS, combining the latest research with real-world insights.Stiff Person Syndrome, SPS, autoimmune disorder, pathogens, infections, molecular mimicry, Celine Dion, Epstein-Barr Virus, Cytomegalovirus, natural therapies, overstimulation, health podcastYou can download your free copy of The Autoimmune RESET here.And you can access all of VJ's free resources here.If you would like to book a free initial consultation with VJ Hamilton, The Autoimmunity Nutritionist, to find out how nutritional therapy and functional medicine could improve your health, you can book an appointment here.Learn more about the functional medicine services at The Autoimmunity Nutritionist Clinic here.Thanks for listening! You can join The Autoimmune Forum on Facebook or find me on Instagram @theautoimmunitynutritionist.

A new paper published in the journal Science entitled, “Persistent complement dysregulation with signs of thromboinflammation in active Long Covid” sheds light on the causes of Long COVID. The authors begin by pointing out the current hypotheses about the causes of Long COVID, including persistent inflammation, autoimmunity, tissue damage, and viral reservoirs. In this study, researchers followed 39 healthy individuals and 113 COVID-19 patients for up to a year to identify biomarkers associated with Long COVID. At the 6-month follow-up, 40 patients still experienced Long COVID symptoms. They collected blood samples and measured over 6500 proteins to identify potential biomarkers using computational tools and experimental evaluation. In patients with Long COVID, there was an increased activation of the complement system, which is a part of the immune system that helps fight pathogens and damaged cells. This activation persists even after the acute phase of the disease. The complement system can cause damage to cell membranes, and in Long COVID patients, there is an imbalance in the formation of a complex called the terminal complement complex (TCC), also known as the membrane attack complex (MAC), which contributes to tissue damage. Long COVID patients experienced increased markers of tissue injury in their blood, along with a thromboinflammatory signature. This means that there are signs of damage to tissues and an abnormal immune response involving the activation of endothelial cells and the breakdown of red blood cells. These findings suggest that Long COVID is associated with ongoing inflammation and potential blood clotting issues. In patients with Long COVID, there are lower levels of antithrombin III, a protein that helps regulate blood clotting. This leads to increased cleavage by thrombin, which is a key factor in the formation of terminal complement complexes (TCCs). Additionally, Long COVID patients show elevated markers of platelet activation and the presence of monocyte-platelet aggregates, particularly in cases where Long COVID symptoms persist for 12 months or more. These patients also exhibit signs of antibody-mediated activation of the classical complement pathway, which is associated with increased levels of antibodies against cytomegalovirus (CMV) and Epstein-Barr virus (EBV). In this study, the researchers also used a sensitive test to measure antinuclear antibodies (ANA) in patients with Long COVID. They found that patients with Long COVID had a higher prevalence of positive ANA results compared to those without Long COVID. Positive ANA tests can indicate autoimmunity. Based on the data presented, it is suggested that Long COVID patients should undergo early cardiovascular assessment due to potential cardiovascular complications. Additionally, antiviral medications targeting SARS-CoV-2 or herpesviruses may help reduce inflammation and blood clotting in Long COVID patients. Therapies that target the terminal complement pathway could also be explored as potential treatment strategies for Long COVID and other post-infection syndromes. Long COVID Clinical Applications This paper confirms that inflammation of the blood vessels is common in Long COVID. Supporting microcirculation with herbs like ginkgo biloba, grape seed extract, and mango fruit powder can help reduce this inflammation and repair damaged blood vessels. These three herbs also are effective anti-viral agents against viruses like Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV). Ginkgo biloba has been shown to help improve the symptoms of Long COVID. I use VascuSelect from Moss Nutrition which contains standardized forms of ginkgo biloba, grape seed extract, and mango fruit powder. I also use palmitoylethanolamide (PEA) combined with luteolin to reduce inflammation and fight chronic viruses. Both of these are found in PEA Luteolin Select from Moss Nutrition.

Introduction: Ryan Courneya is a Lyme disease advocate who delved deep into the intricacies of this illness for years after getting sick and now wishes to share his discoveries and experiences with others. Ryan's Initial Experience with Lyme: Ryan didn't perceive ticks as dangerous, but hindsight reveals their threat. Endured stress from an intense lifestyle, leaning on exercise and supplements for relief. Pursued a career in marketing at Sanford Health, later transitioning through various sales positions. Began to notice health symptoms intensifying, wondering if they were linked to factors like caffeine intake. Medical Journey: Consulted primary care for routine evaluations. Misdiagnosed with occipital neuralgia and sudden onset depression and anxiety, but his health issues persisted. Felt that numerous doctors disregarded his symptoms. A friend proposed that his health issues might stem from Lyme, an idea that was both alarming and affirming for Ryan. Treatment and Recovery: Tested and found positive for European and American strains of Borrelia Burgdorferi, as well as Babesia Microti, Cytomegalovirus (CMV), Parvovirus, and Epstein-Barr Virus (EBV). Leveraged IV Ozone Therapy with an Ultraviolet (UV) component to combat Lyme bacteria. Incorporated the WAVE1 device by FREmedica, a frequency therapy instrument. Used herbal supplements, particularly Doctor Bill Rawls' Lyme protocol grounded in Stephen Buhner's research. Advocated for a proactive mindset as pivotal in the healing journey. Further Exploration and Treatment: Addressed potential mold concerns and explored methodologies for testing both his physique and residence for mold. Investigated treatments tailored for related viruses. Experimented with methylene blue, deducing it's most effective when combined with red light therapy. Underwent SOT Therapy, a method crafted to pinpoint and exterminate specific pathogens. In Ryan's case, it was directed at Borrelia Burgdorferi, the Lyme-inducing bacterium. Conclusion: Ryan emphasizes that while it's beneficial to reduce and manage pathogens, one doesn't need to eradicate all of them to maintain good health. He notes that certain microbes, like EBV, might remain but can coexist with a strong immune system in a balanced state. Stresses the significance of understanding one's life purpose in confronting chronic diseases. Ryan continues to assist others by recounting his journey. For a deeper insight into Ryan Courneya's healing trajectory and the therapeutic methods he embraced, tune into the complete episode on our website or any primary podcast platform.

What if your newborn was diagnosed with hearing loss? How would you navigate the intricate journey of early diagnosis, the emotional toll, and strategizing the best possible care for your child? Nicky Hemann from Starkey's HR leadership team shares her experience raising her daughter Kaylee, who presents with a severe to profound hearing loss as a result of Cytomegalovirus (CMV).   From the shock of the initial diagnosis to having her daughter implanted with cochlear implants, Nicky unfolds the narrative of her family's experience. You'll glean invaluable insights as Nicky shares their routine of attending both an oral school and a deaf school, and the underlying importance of allowing Kaylee to choose her preferred mode of communication. We conclude this episode with Nicky's advice for parents grappling with similar situations, advice for professionals on how to best communicate difficult news to patients, and her heartfelt account of how she's helping Kaylee lead a fulfilling life. Tune in to our episode to learn about the power of support and awareness.    Link to Full Transcript

Epstein-Barr Virus(EBV) a.k.a. “Mono” or the “Kissing Disease”, Cytomegalovirus (CMV), and the lessor known Adenovirus (AV) (all are forms of Herpes Virus), have been the cause of misery and suffering for decades, even centuries in people around the world. They are leading causes Chronic Fatigue Syndrome a.k.a. “Cfers” and cause a host of symptoms from severe fatigue to muscle and joint pain, well the list is very long. One method of Intravenous Ozone Therapy has been proven over the last three decades to eliminate it, permanently, completely, once and for all and even CURE it!

Epstein-Barr Virus(EBV) a.k.a. “Mono” or the “Kissing Disease”, Cytomegalovirus (CMV), and the lessor known Adenovirus (AV) (all are forms of Herpes Virus), have been the cause of misery and suffering for decades, even centuries in people around the world. They are leading causes Chronic Fatigue Syndrome a.k.a. “Cfers” and cause a host of symptoms from severe fatigue to muscle and joint pain, well the list is very long. One method of Intravenous Ozone Therapy has been proven over the last three decades to eliminate it, permanently, completely, once and for all and even CURE it!

Epstein-Barr Virus(EBV) a.k.a. “Mono” or the “Kissing Disease”, Cytomegalovirus (CMV), and the lessor known Adenovirus (AV) (all are forms of Herpes Virus), have been the cause of misery and suffering for decades, even centuries in people around the world. They are leading causes Chronic Fatigue Syndrome a.k.a. “Cfers” and cause a host of symptoms from severe fatigue to muscle and joint pain, well the list is very long. One method of Intravenous Ozone Therapy has been proven over the last three decades to eliminate it, permanently, completely, once and for all and even CURE it!

Do you know how to reduce the transmission risk of CMV, the most common virus causing birth defects in the United States? Credit available for this activity expires: 12/23/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/985889?ecd=bdc_podcast_libsyn_mscpedu

CMV is a common and yet permanent infection that poses risks to people with weakened immune systems. In this episode, Prof. Joe Sasadeusz sets the scene by giving an overview of these infections alongside patient advocate, Ms Lisa Foster. CMV infections have serious consequences, especially those in high-risk groups, such as those with AIDS, and patients who are receiving immunosuppressants following a solid organ (SOT) or hematopoietic stem cell transplant (HSCT).See omnystudio.com/listener for privacy information.

Cytomegalovirus is VERY common and VERY contagious. Chances are you may have caught it already and if not, you will. Some people get over it pretty quickly. And for others, it causes chronic fatigue. In this episode, I break down the acute and chronic symptoms of cytomegalovirus (CMV) and how you can get tested and eliminate it from your body to get your energy and health back. Find out more: https://integrativemedica.com --- Send in a voice message: https://podcasters.spotify.com/pod/show/jake-schmutz/message

In this episode, we review the high-yield topic of Cytomegalovirus (CMV) from the Pediatrics section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

In this episode, Shannon Jackson, The Peoples Nurse, will be joined by Sarah Streeval to discuss CMV and celebrate "Bella's Law "for National Cytomegalovirus (CMV) awareness month. Cytomegalovirus (CMV) is a common virus for people of all ages; however, a healthy person's immune system usually keeps the virus from causing illness.In the United States, nearly one in three children is already infected with CMV by age five. Over half of adults have been infected with CMV by age 40. Once CMV is in a person's body, it stays there for life and can reactivate. A person can also be re-infected with a different strain (variety) of the virus. Most people with CMV infection have no symptoms and aren't aware that they have been infected.Babies born with CMV can have brain, liver, spleen, lung, and growth problems. The most common long-term health problem in babies born with congenital CMV infection is hearing loss, which may be detected soon after birth or later in childhood.

Listen as Dr. Megan Pesch shares her journey to becoming a parent advocate and a researcher in Cytomegalovirus (also called CMV). Dr. Pesch is an Assistant Professor of Developmental and Behavioral Pediatrics at the University of Michigan where she is the Director of the Congenital CMV Developmental Follow-up Clinic. Dr. Pesch completed her medical school training, residency, and fellowship at the University of Michigan. She is board certified in Developmental and Behavioral Pediatrics and serves as the President-elect of the National CMV Foundation. Dr. Pesch's youngest daughter has a profound bilateral sensorineural hearing loss from congenital CMV and this led to her involvement in national advocacy efforts to ensure that all newborns receive CMV screening.  Dr. Pesch's clinical interests include the early diagnosis and treatment of congenital CMV using a multidisciplinary approach with a focus on family care and support, while her research focuses on healthcare provider practices around congenital CMV diagnosis and management and understanding the relationship between autism and CMV.   The month of June is CMV awareness month. Please visit the National CMV foundation to learn more about advocacy efforts in CMV in your area and how you can support NBS for CMV.   Learn more about Dr. Megan Pesch and her advocacy effort on newborn screening for CMV: https://ihpi.umich.edu/our-experts/pesch https://www.nationalcmv.org   Podcast Interview Question with Dr. Megan Pesch. You are currently an Assistant Professor of Developmental and Behavioral Pediatrics and the Director of the Congenital CMV Developmental Follow-up Clinic at the University of Michigan. Can you tell our listeners more about CMV and how it impacts mothers, their babies and families? (perhaps, talk about the differences between prenatal CMV and neonatal congenital CMV)? You are a clinician and a researcher, and lead efforts in the Pesch Lab at Michigan Medicine at the University of Michigan! One of your projects brings together a multidisciplinary group of health care providers to refer infants who fail their newborn hearing screen for congenital cytomegalovirus testing. Tell us more about this important project and explain how you got involved in newborn screening research? Currently, there is no standard of care or routine screening for newborns for congenital cytomegalovirus at birth. What can parents do if they suspect their baby has CMV? (perhaps discuss the Alethia CMV Assay Test System) What is hearing targeted early cytomegalovirus (HT-CMV) screening? One of your current studies seeks to understand the possible connection between exposure to CMV during pregnancy and the later risk of autism. Can you tell us more about this effort? What are you hoping to learn? What is the biological pathway? You are also the President-elect of the National CMV Foundation. What are some of the current activities or programs that people can get involved in your advocacy efforts? What are the recent advocacy efforts to support newborn screening for CMV? Is it currently being reviewed to be added to the RUSP? Are you involved in training the next generation of pediatricians, and what do you tell them about newborn screening research? You are busy as a clinician, researcher, advocate, and parent. Do you have any stories of inspiration that keep you going? What does NBS research mean to you? To learn how NBSTRN can help your research in newborn screening, visit www.nbstrn.org  

Christine Salvatore M.D. and Sallie Permar M.D., Ph.D. discuss congenital cytomegalovirus (CMV). They share what patients should know about CMV and recent advancements in vaccine development for the infection. They discuss goals to create a multidisciplinary collaborative Congenital Infection Clinic at Weill Cornell Medicine to treat CMV. The providers also highlight the partnership with government affairs towards an initiative for state legislation around CMV education and advocacy for universal testing.Additionally, Dr. Permar highlights her groundbreaking work on mother-to-child transmission of viruses including HIV and CMV, which recently earned her the prestigious 2020-21 Society of Pediatric Research Award, in Honor of E. Mead Johnson.To schedule with Christine Salvatore M.D., To schedule with Sallie Permar M.D

In this episode, we review the high-yield topic of Cytomegalovirus (CMV) from the Microbiology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

In this episode, we review the high-yield topic of Cytomegalovirus (CMV) from the Infectious Disease section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Cytomegalovirus (CMV) retinitis continues to challenge retina specialists. Could use of CMV-specific cytotoxic T lymphocytes be an effective strategy in some patients? And if so, in whom? To answer these questions, Christina Weng, MD, MBA, is joined by study author Mrinali Gupta, MD, and panelists Brian Do, MD, and Dimitra Skondra, MD, PhD. During their discussion, we hear about the structure and findings of the study and learn about how these new data may affect treatment algorithms for patients with newly diagnosed CMV retinitis. 

The ladies of the Scrub Caps and Sippy Cups podcast are joined by fellow CRNA mom, Alex Pudwill as she shares her son’s journey with congenital Cytomegalovirus (CMV). Her son Sam was suspected to have been exposed to CMV in the third trimester of pregnancy. Alex explains the signs and symptoms of CMV at birth and how she and Sam’s medical providers came to realize he had congenital CMV. Alex shares her struggles with mom guilt and how their family focuses on Sam’s milestones to keep them going. Alex is here to spread awareness about congenital CMV and help prevent this from occurring.  There are two groups of people that are most at risk for contracting CMV, immunocompromised individuals and unborn babies. Alex and Sam’s medical providers did not have any reason to suspect Sam had CMV in utero. He was growing fine and there was not a cause for concern during prenatal exams. She was shocked when she first saw him and he was covered in petechiae and had a blueberry muffin rash. Sam was sent to the Neonatal Intensive Care Unit (NICU) where he was cared for in the coming days.  Alex shares the struggles ahead for Sam and what it is like to have a child with CMV. From making the decision to have Sam receive cochlear implants to a brain bleed that will cause long-term issues and how she and her family overcame these obstacles.  Laci asks if there is any treatment for moms in the event that they are found to be positive for CMV while pregnant. Alex explains that there are antivirals available, but the treatments are experimental at this time. Ellen discusses the concerns from a perspective of being pregnant and not knowing what she could come in contact with and if that would have an effect on her baby. For many parents, this is currently a COVID concern. What effects does this have on the baby?  Alex gives tips on how moms can help decrease their chances of getting CMV while pregnant and shares some statistics with our listeners.   “91% of women are unaware of congenital CMV. 1:200 children are born with CMV each year and 1:10 of those are born with a disability.” Alex wants to get the message out about congenital CMV and what we can do as moms and healthcare professionals to prevent this virus from spreading. Please share this episode with a friend who could benefit from this information!  Alex Pudwill is a CRNA mom from Sioux Falls, SD. Her son, Sam, was born with congenital CMV. Ever since then, she has been trying to educate as many moms and soon-to-be moms as possible to prevent this very preventable disease. You can follow Alex Pudwill @aapudwill on Instagram and on Facebook at https://www.facebook.com/alex.hughes.1238 Let's connect! Follow the girls on Instagram - @mslacilea @ellenlauletta @stl_injector Email: scrubcapsandsippycups@gmail.com Or you can leave us an audio message that could air on a future podcast episode! https://www.speakpipe.com/Scrubcapsandsippycups Facebook: Scrub Caps and Sippy Cups Instagram: @heysmartmommas Twitter: @heysmartmommas

Jaclyn Greenberg did not know she had contracted Cytomegalovirus (CMV) during her second pregnancy until her 34-week check-up when doctors discovered her baby was not growing correctly, had fluid in his brain, and had an enlarged heart. Jaclyn was rushed to the hospital to have an emergency C-Section and after she delivered Henry spent that whole summer practically living in the NICU.  Because Henry’s brain stopped developing between 30 and 32 weeks his medical team didn’t know what he would ultimately be capable of, or even if he would live. Jaclyn’s sense of guilt overwhelmed her and she entered a deep depression. She stopped visiting the hospital as often and when she was at work or with her other child, relied on others to take care of Henry in ways that she felt unable to.  Then, one day she began to feel better and she realized she wanted to enjoy the life she had with her family life and stop trying to fix what could not be fixed. Jaclyn became an advocate for her son and began insisting on getting medical care with doctors who see beyond Henry’s disabilities and treat him like a whole person. Jaclyn is now a mother of three and has made it her mission to battle the stigma the differently-abled face, educate others, and spend quality time with her husband and her children, all of whom look out for each other unconditionally and remind her every day how far they have come as a family.  Connect with Jaclyn:Instagram Connect With Ronit:For more about this episode click here!InstagramFacebook

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

In this episode we’re welcoming Professor Paul Griffiths, from the Royal Free hospital and University College London. Professor Griffiths - who is a clinician by training - came to the CVR in Glasgow earlier this year to give a seminar. Connor (an ex CVR-postdoc) caught up with Paul in this episode and discuss his favourite virus, human cytomegalovirus (CMV), the road to making and testing vaccines against this very important virus, and his surprising side career as an author of factual and fictional science-inspired books. As always, you can find our previous content on herpesviruses and vaccines over at cvrblog.myportfolio.com, email us at cvrcontagiousthinking@gmail.com or tweet us @CVRblog You can find out more about CMV from the NHS here: https://www.nhs.uk/conditions/cytomegalovirus-cmv/ Featuring: Paul Griffiths and Connor Bamford, Editing: Connor Bamford Music: Siesta by Javier Suarez (jahzzar)

Cytomegalovirus (CMV) is more common than the Zika virus, yet few people know about the irreversible birth defects congenital CMV infection can cause. Jeff Baxter, CEO of VBI Vaccines, talks about the risks CMV poses to pregnant women and their unborn babies. Currently, there is no way to prevent contracting CMV during pregnancy and the irreversible birth defects that can result. Thankfully, VBI Vaccines is currently developing a vaccine to prevent CMV. If successful, this could be given to all adolescent-aged young women as a preventive measure. @VBIVaccines VBIVaccines.com #CMV   #congenitalCMV   #CMVawareness #vaccine   #CMVinfection   #stopCMV VB  

Areas of discussion include Epidemiology (Natural History; Mode of Transmission and Types of Infections), Virology of CMV (Characteristics of Cytomegalovirus (CMV), Replication and Viral Infection, and Disease syndromes), Molecular Detection of an CMV (Signal Amplification; Target Amplification), Management of CMV Disease, and The Future of CMV Molecular testing. Speaker: Art Braden, Ph.D., Roche Diagnostics

Cytomegalovirus (CMV) is frequently transmitted by solid organ transplantation and is associated with graft failure. By forming the boundary between circulation and organ parenchyma, endothelial cells (EC) are suited for bidirectional virus spread from and to the transplant. We applied Cre/loxP-mediated green-fluorescence-tagging of EC-derived murine CMV (MCMV) to quantify the role of infected EC in transplantation-associated CMV dissemination in the mouse model. Both EC- and non-EC-derived virus originating from infected Tie2-cre(+) heart and kidney transplants were readily transmitted to MCMV-naïve recipients by primary viremia. In contrast, when a Tie2-cre(+) transplant was infected by primary viremia in an infected recipient, the recombined EC-derived virus poorly spread to recipient tissues. Similarly, in reverse direction, EC-derived virus from infected Tie2-cre(+) recipient tissues poorly spread to the transplant. These data contradict any privileged role of EC in CMV dissemination and challenge an indiscriminate applicability of the primary and secondary viremia concept of virus dissemination.

Cytomegalovirus (CMV), similar to other members of the Herpesviridae family, can establish both persistent and latent infections. Each of the CMVs that are found in many animal species replicates in the salivary gland, and oral secretion represents a source of horizontal transmission. Locally restricted replication characterizes the immunocompetent individual, whereas in the immunocompromised host, protean disease manifestations occur due to virus dissemination. The virus is cleared by immune surveillance, and CD8+ T lymphocytes play a major role. Remarkably, certain cell types of salivary gland tissues are exempt from CD8+ T-lymphocyte control of murine CMV infection and require the activity of CD4+ T lymphocytes. The results presented here suggest that this activity is a function of Th1 cells. Neutralization of endogenous gamma interferon abrogated the antiviral activity of Th1 cells but not that of CD8+ T lymphocytes in other tissues. Neutralization of endogenous gamma interferon did not interfere with the induction of the cellular and humoral immune response but acted during the effector phase. Recombinant gamma interferon could not replace the function of Th1 cells in vivo and had limited direct antiviral activity in vitro. The results therefore suggest that gamma interferon represents one, but not the only, essential factor involved in salivary gland clearance, establishment of CMV latency, and, eventually, the control of horizontal transmission.